These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21886510)

  • 1. US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.
    Hornberger J; Chien R; Krebs K; Hochheiser L
    J Oncol Pract; 2011 May; 7(3 Suppl):e38s-45s. PubMed ID: 21886510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. US insurance program's experience with a multigene assay for early-stage breast cancer.
    Hornberger J; Chien R; Krebs K; Hochheiser L
    Am J Manag Care; 2011 May; 17(5 Spec No):e194-202. PubMed ID: 21711071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer.
    Hannouf MB; Xie B; Brackstone M; Zaric GS
    BMC Cancer; 2012 Oct; 12():447. PubMed ID: 23031196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in post-menopausal women with early-stage estrogen or progesterone-receptor-positive, axillary lymph-node positive breast cancer.
    Hannouf MB; Xie B; Brackstone M; Zaric GS
    Pharmacoeconomics; 2014 Feb; 32(2):135-47. PubMed ID: 24288208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.
    Hornberger J; Cosler LE; Lyman GH
    Am J Manag Care; 2005 May; 11(5):313-24. PubMed ID: 15898220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization.
    Klang SH; Hammerman A; Liebermann N; Efrat N; Doberne J; Hornberger J
    Value Health; 2010; 13(4):381-7. PubMed ID: 20412544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada.
    Torres S; Trudeau M; Gandhi S; Warner E; Verma S; Pritchard KI; Petrella T; Hew-Shue M; Chao C; Eisen A
    Oncologist; 2018 Jul; 23(7):768-775. PubMed ID: 29371476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
    Partin JF; Mamounas EP
    Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in Ireland.
    McSorley LM; Tharmabala M; Al Rahbi F; McSorley K; Chew S; Evoy D; Geraghty JG; Prichard RS; Rothwell J; McCartan DP; McDermott EW; Keane M; Kennedy MJ; O'Reilly S; Millen SJ; Crown JP; Smyth LM; Kelly CM; Quinn CM; Walshe JM
    Breast Cancer Res Treat; 2021 Aug; 188(3):789-798. PubMed ID: 33835293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and economic impact of the 21-gene recurrence score assay in adjuvant therapy decision making in patients with early-stage breast cancer: pooled analysis in 4 Basque Country university hospitals.
    Martínez Del Prado P; Alvarez-López I; Domínguez-Fernández S; Plazaola A; Ibarrondo O; Galve-Calvo E; Ancizar-Lizarraga N; Gutierrez-Toribio M; Lahuerta-Martínez A; Mar J
    Clinicoecon Outcomes Res; 2018; 10():189-199. PubMed ID: 29593426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of 21-gene recurrence score on chemotherapy decisions for patients with estrogen receptor-positive, epidermal growth factor receptor 2-negative and lymph node-negative early stage-breast cancer].
    Mao Y; Chen XS; Liang Y; Wu JY; Huang O; Zong Y; Fang Q; He JR; Zhu L; Chen WG; Li YF; Lin L; Fei XC; Shen KW
    Zhonghua Zhong Liu Za Zhi; 2017 Jul; 39(7):502-508. PubMed ID: 28728295
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
    Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
    Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and ≥31.
    Berger NF; Zimmerman BS; Tharakan S; Suchman K; Cascetta KP; Blanter J; Moshier E; Ru M; Jaffer S; Tiersten A
    Oncology; 2021; 99(11):699-702. PubMed ID: 34425579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-utility analysis of 21-gene assay for node-positive early breast cancer.
    Masucci L; Torres S; Eisen A; Trudeau M; Tyono I; Saunders H; Chan KW; Isaranuwatchai W
    Curr Oncol; 2019 Oct; 26(5):307-318. PubMed ID: 31708649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of TAILORx on chemotherapy prescribing and 21-gene recurrence score-guided treatment costs in a population-based cohort of patients with breast cancer.
    Tesch ME; Speers C; Diocee RM; Gondara L; Peacock SJ; Nichol A; Lohrisch CA
    Cancer; 2022 Feb; 128(4):665-674. PubMed ID: 34855202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of 21-gene recurrence score assay for hormone receptor-positive, lymph node-negative breast cancer in early stage.
    Yu-Qing Y; Lei W; Mei-Ling H; Jing-Jing X; Mei-Chen W; Jiang W; Jun-Sheng H; Rui L; Nan-Lin L
    Exp Mol Pathol; 2019 Jun; 108():150-155. PubMed ID: 31026440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The budget impact of utilizing the Oncotype DX Breast Recurrence Score test from a US healthcare payer perspective.
    Berdunov V; Laws E; Cuyun Carter G; Luo R; Russell C; Campbell S; Force J; Abdou Y
    J Med Econ; 2023; 26(1):973-990. PubMed ID: 37466220
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.